Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse

被引:11
|
作者
Yoo, Kyung Hyun [1 ]
Kim, Yo Na [2 ]
Lee, Min Joo [1 ]
Seong, Je Kyung [2 ]
Park, Jong Hoon [1 ]
机构
[1] Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea
[2] Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul, South Korea
关键词
ApolipoproteinA1; Autosomal dominant polycystic kidney disease; Inflammation; Mxi1; Renal fibrosis; NECROSIS-FACTOR-ALPHA; A-I; TGF-BETA; MXI1; LIPOPROTEIN(A); INACTIVATION; ACTIVATION; EXPRESSION; MUTATION; DISEASE;
D O I
10.1002/pmic.200800753
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Autosomal dominant polycystic kidney disease is one of the most common human monogenic diseases in which extensive epithelial-lined cysts develop in kidney and other organs. Affected kidneys are not only characterized by the formation of cysts, but also by changes associated with the extracellular matrix and interstitial inflammation, which can progress to fibrosis and loss of renal function. Mxi1 protein, which is a c-myc antagonist, may be essential in controlling cellular growth and differentiation. Previously, multiple tubular cysts were observed in kidney of Mxi1-deficient mice aged 6 months and more. Presently, 2-DE and MALDI-TOF MS was employed to identify the differentially expressed proteins in the kidney. Several proteins were identified, among them, apolipoproteinA1 which is a major component of the high-density lipoprotein complex and has anti-inflammation effects, was significantly decreased in the Mxi1-deficient mouse. We confirm the development of inflammation and renal fibrosis and the expression of extracellular matrix molecules including transforming growth factor were also increased in cystic kidney. These results indicate that expression of proteins related with inflammation and renal fibrosis changes by Mxi1 inactivation in polycystic kidney.
引用
收藏
页码:3824 / 3832
页数:9
相关论文
共 46 条
  • [41] Age-Dependent Hippocampal Proteomics in the APP/PS1 Alzheimer Mouse Model: A Comparative Analysis with Classical SWATH/DIA and directDIA Approaches
    van der Spek, Sophie J. F.
    Gonzalez-Lozano, Miguel A.
    Koopmans, Frank
    Miedema, Suzanne S. M.
    Paliukhovich, Iryna
    Smit, August B.
    Li, Ka Wan
    CELLS, 2021, 10 (07)
  • [42] Localisation of RA175 (Cadm1), a cell adhesion molecule of the immunoglobulin superfamily, in the mouse testis, and analysis of male infertility in the RA175-deficient mouse
    Maekawa, M.
    Ito, C.
    Toyama, Y.
    Suzuki-Toyota, F.
    Fujita, E.
    Momoi, T.
    Toshimori, K.
    ANDROLOGIA, 2011, 43 (03) : 180 - 188
  • [43] Identification of Three Novel Frameshift Mutations in the PKD1 Gene in Iranian Families with Autosomal Dominant Polycystic Kidney Disease Using Efficient Targeted Next-Generation Sequencing
    Ranjzad, Fariba
    Aghdami, Nasser
    Tara, Ahmad
    Mohseni, Marzieh
    Moghadasali, Reza
    Basiri, Abbas
    KIDNEY & BLOOD PRESSURE RESEARCH, 2018, 43 (02) : 471 - 478
  • [44] RNA interference-mediated knockdown of SIRT1 and/or SIRT2 in melanoma: Identification of downstream targets by large-scale proteomics analysis
    Wilking-Busch, Melissa J.
    Ndiaye, Mary A.
    Liu, Xiaoqi
    Ahmad, Nihal
    JOURNAL OF PROTEOMICS, 2018, 170 : 99 - 109
  • [45] Whole-Transcriptome Analysis of APP/PS1 Mouse Brain and Identification of circRNA-miRNA-mRNA Networks to Investigate AD Pathogenesis
    Ma, Nana
    Pan, Jie
    Ye, Xiaoyang
    Yu, Bo
    Zhang, Wei
    Wan, Jun
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 18 : 1049 - 1062
  • [46] Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
    Marten A. Lantinga
    Hedwig M. A. D’Agnolo
    Niek F. Casteleijn
    Johan W. de Fijter
    Esther Meijer
    Annemarie L. Messchendorp
    Dorien J. M. Peters
    Mahdi Salih
    Edwin M. Spithoven
    Darius Soonawala
    Folkert W. Visser
    Jack F. M. Wetzels
    Robert Zietse
    Joost P. H. Drenth
    Ron T. Gansevoort
    Drug Safety, 2017, 40 : 153 - 167